• INCLUSION CRITERIA:
• Participant must be scheduled to undergo standard of care prostatectomy for presumed localized prostate cancer at the NIH Clinical Center.
• Recent (within 12 months of study entry) trans-rectal biopsy indicating the presence of adenocarcinoma of the prostate gland in which at least sextant biopsies were obtained. Knowledge of the location of each specimen is required for inclusion.
• Participant must be 18 years or older.
• Serum creatinine within 1 week prior to MR imaging less than or equal to 1.8mg/dl AND eGFR must be greater than 30 ml/min/1.73(m2)
• ECOG Performance score of 0 or 1.
• Ability to provide informed consent. All patients must sign a document of informed consent indicating their understanding of the investigational nature and risks of the study before any protocol related studies are performed.

EXCLUSION CRITERIA:

• Known allergy to gadolinium or acetate.
• Participants for whom participating would significantly delay the scheduled standard of care therapy.
• Participants with any coexisting medical or psychiatric condition that is likely to interfere with study procedures and/or results are excluded.
• Participants with severe claustrophobia.
• Patients with contraindications to MRI
• Patients weighing greater than 136 kg (weight limit for scanner table).
• Patients with pacemakers, cerebral aneurysm clips, shrapnel injury, or other implanted electronic devices or metal not compatible with MRI.
• Patients with contraindication to endorectal coil placement
• Severe hemorrhoids.
• Surgically absent rectum.
• Other medical conditions deemed by the PI or associates to make the patient ineligible for protocol procedures.
• Patients who have previously received radiation therapy to the pelvis.
• Patients who have received androgen deprivation therapy.